This is a non-core endpoint: only basic statistics are computed.

Increased secretion of glucagon

E4_GLUCAGONPLUS

No definition available.

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — E16.3 Hospital discharge: ICD-9 — 2514 Cause of death: ICD-10 — E16.3 Cause of death: ICD-9 — 2514 2 out of 7 registries used, show all original rules.	13
4. Check minimum number of events None	13
5. Include endpoints None	13
6. Filter based on genotype QC (FinnGen only)	13

Control definitions (FinnGen only)

Control exclude: E4_GLUCOPANCREAS

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: E16
Name in latin: Hypersecretio glucagoni

NAME	E4_GLUCAGONPLUS
CONTROL_EXCLUDE	E4_GLUCOPANCREAS
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	E163
HD_ICD_9	2514
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	E163
COD_ICD_9	2514
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Increased secretion of glucagon based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Not enough data for upset plot.

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	93	44	48
Only index persons	59	31	28
Unadjusted period prevalence (%)
Whole population	0.00	0.00	0.00
Only index persons	0.00	0.00	0.00
Median age at first event (years)
Whole population	55.19	57.76	52.31
Only index persons	48.13	52.57	43.22

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	13	6	7
Unadjusted period prevalence (%)	0.00	0.00	0.00
Median age at first event (years)	41.91	41.68	42.11

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

unit

cases

controls

-log₁₀(p)

N cases

N controls

(3020779) Urea [Moles/volume] in Serum or Plasma

16.91

3.95

22.7

11.2

mmol/l

14.2

10.3

—

(3004789) Transferrin [Mass/volume] in Serum or Plasma

9.41

3.27

3.7

1.6

g/l

2.1

2.5

—

(3021447) Carbon dioxide [Partial pressure] in Venous blood

12.43

3.02

5.0

3.0

kpa

5.7

5.0

—

(3024354) Oxygen [Partial pressure] in Venous blood

12.43

3.02

4.6

3.0

kpa

4.3

4.9

—

(3012544) pH of Venous blood

10.61

2.81

5.0

2.9

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

10.61

2.81

1.2

1.7

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

7.53

2.62

2.5

1.5

—

(3018677) aPTT in Platelet poor plasma by Coagulation assay

7.53

2.62

2.3

1.5

31.7

32.4

—

(3023368) Bacteria identified in Blood by Culture

6.29

2.59

5.3

5.6

—

(3014576) Chloride [Moles/volume] in Serum or Plasma

6.94

2.49

3.2

13.3

mmol/l

100.2

105.1

—

(3007853) Bacteria identified in Skin by Aerobe culture

5.24

2.03

1.5

1.4

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

4.93

1.93

2.7

1.4

—

(3041096) Erythrocytes [Presence] in Urine by Automated

4.39

1.86

18.9

2.9

—

(3042936) Bacteria identified in Isolate by Culture

4.64

1.84

4.5

1.7

—

(3026008) Bacteria identified in Urine by Culture

4.20

1.78

4.6

2.1

—

(42870588) Differential panel, method unspecified - Blood

4.20

1.78

4.4

4.6

—

(3033658) Prothrombin time (PT) actual/Normal

3.56

1.45

8.0

3.4

117.5

97.4

—

(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma

3.56

1.45

2.3

2.1

mg/l

1.5

3.0

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

3.21

1.21

1.8

3.1

—

(3022096) Basophils/100 leukocytes in Blood

3.21

1.19

13.1

3.6

0.9

0.6

—

(3006504) Eosinophils/100 leukocytes in Blood

3.00

1.14

13.1

3.9

3.0

2.9

—

(3019069) Monocytes/100 leukocytes in Blood

3.00

1.14

13.1

4.2

10.2

8.2

—

(3002030) Lymphocytes/100 leukocytes in Blood

2.90

1.11

14.0

4.2

24.7

28.3

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

3.09

1.10

2.3

2.2

—

(3044640) Blood type and Crossmatch panel - Blood

2.70

0.93

3.7

2.2

—

(3018010) Neutrophils/100 leukocytes in Blood

2.80

0.88

14.0

3.9

60.2

57.9

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

2.74

0.86

3.2

2.0

—

(40758558) Short blood count panel - Blood

2.60

0.83

2.2

11.7

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

2.17

0.61

4.8

3.6

—

(3003694) ABO and Rh group [Type] in Blood

1.83

0.48

1.4

1.8

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

0.00

0.44

0.0

2.1

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

0.00

0.44

0.0

1.5

—

(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma

0.00

0.43

0.0

1.7

—

(40768804) Tissue Pathology biopsy report

1.51

0.26

1.7

2.0

—

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

0.00

0.22

0.0

1.4

—

(21494755) Public health laboratory ask at order entry panel

0.00

0.22

0.0

1.2

—

(3043109) Cytology report of Tissue fine needle aspirate Cyto stain

0.00

0.0

1.2

—

(3018405) Lactate [Moles/volume] in Arterial blood

0.00

0.0

13.8

—

0.9

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

0.00

0.0

1.3

—

(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain

0.00

0.0

1.2

—

(3017895) Helicobacter pylori Ab [Units/volume] in Serum

0.00

0.0

1.5

—

(3004490) Bicarbonate [Moles/volume] standard in Capillary blood

0.00

0.0

1.2

—

23.9

—

(3028026) IgM [Mass/volume] in Serum or Plasma

0.00

0.0

1.3

—

1.0

—

(40768443) Skin Pathology biopsy report

0.00

0.0

1.2

—

(40761536) Microorganisms panel - Urine sediment

0.00

0.0

3.4

—

(3000764) Benzodiazepines [Presence] in Urine

0.00

0.0

1.0

—

(3016879) Cocaine [Presence] in Urine

0.00

0.0

1.0

—

(3019225) pH of Specimen

0.00

0.0

2.4

—

(3045414) Leukocytes [Presence] in Urine

0.00

0.0

1.2

—

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

0.00

0.0

1.6

—

(3044889) 12 lead EKG panel

0.91

0.00

4.0

3.1

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

0.0

1.1

—

(3046870) Tissue transglutaminase IgG Ab [Units/volume] in Serum

0.00

0.0

1.1

—

(1002224) Polysomnography panel

0.00

0.0

1.0

—

(3004716) Salmonella sp identified in Stool by Organism specific culture

0.00

0.0

1.2

—

(3048816) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood

0.00

0.0

1.6

—

1.2

—

(3027944) Amphetamines [Presence] in Urine

0.00

0.0

1.0

—

(3028300) Cannabinoids [Presence] in Urine

0.00

0.0

1.0

—

(3027008) Opiates [Presence] in Urine

0.00

0.0

1.0

—

(3004248) Sex hormone binding globulin [Moles/volume] in Serum or Plasma

0.00

0.0

1.1

—

27.2

—

Mortality – FinRegistry

↥

Association

Association between endpoint E4_GLUCAGONPLUS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have E4_GLUCAGONPLUS.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: E4_GLUCAGONPLUS – Increased secretion of glucagon

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Increased secretion of glucagon

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints